biotinylated red blood cells
Cell therapyexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02075970)
Timeline
Indications
Mechanism of action
- ErythrocyteSupplementation
Erythrocyte supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- biotinylated red blood cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06313398 | Early Phase 1 (Phase 1) | May 17, 2024 | Georgetown University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT04426591 | Phase 1 | Jun 30, 2020 | Emory University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT03364686 | Phase 2 | Oct 31, 2018 | National Heart, Lung, and Blood Institute (NHLBI), University of Pittsburgh |
| NCT02075970 | Phase 2 | Jun 1, 2014 | Department of Health and Human Services, Janssen Pharmaceutica NV, National Heart, Lung, and Blood Institute (NHLBI), University of Iowa |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 4 | 1 | 2 | 2014 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2014 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Georgetown University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2014 |
| University of Iowa | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2018 |
7 organizations
Page 1 / 1